miR-30d-5p promotes beta cell recovery and immunomodulation in type 1 diabetes - Scorecard - MDSpire

miR-30d-5p promotes beta cell recovery and immunomodulation in type 1 diabetes

  • By

  • Laia Gomez-Muñoz

  • David Perna-Barrull

  • Dagmar Klein

  • Silvia Alvarez-Cubela

  • Gerard Godoy-Tena

  • Daniel A Cook

  • Catalina Quimper Voto-Bernales

  • Mayur Doke

  • Marta Murillo

  • Aina Valls

  • Ricardo Luis Pastori

  • Juan Dominguez-Bendala

  • Marta Vives-Pi

  • June 2, 2026

  • 0 min

Share

Clinical Scorecard: miR-30d-5p Enhances Beta Cell Regeneration and Immune Regulation in Type 1 Diabetes

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationChildren with Type 1 Diabetes, particularly during the partial remission phase.
Care Setting

Key Highlights

  • miR-30d-5p is upregulated during the partial remission phase in children with T1D.
  • Transfection of human pancreatic slices with miR-30d-5p enhances insulin secretion.
  • Treatment with miR-30d-5p in NOD mice delays diabetes onset.
  • miR-30d-5p modulates expression of inhibitory molecules in human T lymphocytes.
  • The study highlights the interplay between immune and epigenetic mechanisms in T1D.
  • Inhibition of miR-30d-5p may worsen autoimmune attack.

Guideline-Based Recommendations

Diagnosis

    Management

    • Consider the role of miR-30d-5p in therapeutic strategies for preserving beta cell function, including potential miR-30d-5p mimetics.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Pediatric patients with Type 1 Diabetes experiencing partial remission.

        miR-30d-5p may enhance beta cell regeneration and immune regulation.

        Clinical Best Practices

        • Investigate the epigenetic dynamics during the partial remission phase.
        • Utilize RNA sequencing to identify transcriptional changes in beta cells.
        • Monitor T cell phenotyping and cytokine secretion in patients with T1D.
        • Regularly assess levels of miR-30d-5p in clinical practice.

        Related Resources & Content

        Original Source(s)

        miR-30d-5p promotes beta cell recovery and immunomodulation in type 1 diabetes

        • by Laia Gomez-Muñoz, David Perna-Barrull, Dagmar Klein, Silvia Alvarez-Cubela, Gerard Godoy-Tena, Daniel A Cook, Catalina Quimper Voto-Bernales, Mayur Doke, Marta Murillo, Aina Valls, Ricardo Luis Pastori, Juan Dominguez-Bendala, Marta Vives-Pi

        • June 2, 2026

        Related Content

        From risk factors to molecular targets: clinical associations and molecular docking insights into phthalate-associated diabetic retinopathy

        A clinically interpretable machine learning model for early detection of diabetic retinopathy in multiple community health centers

        Could Wegovy Raise Optic Nerve Risk?

        A pharmacovigilance analysis of FDA adverse event reports finds the strongest ischemic optic neuropathy reporting signal with high-dose semaglutide formulations, with higher adjusted odds reported in men.